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Nanotechnology-Based Targeted Drug Delivery: An
Emerging Tool to Overcome Tuberculosis
Zsuzsa Baranyai,* Héctor Soria-Carrera, Maria Alleva, Ana C. Millán-Placer,
Ainhoa Lucía, Rafael Martín-Rapún, José A. Aínsa, and Jesús M. de la Fuente*
The appearance and rapid spread of drug resistant strains of tuberculosis
(TB), one of the deadliest infectious diseases, pose a serious threat to public
health and increase the need for shorter, less toxic, and more effective
therapies. Developing new drugs is difficult and often associated with side
effects, so nanotechnology has emerged as a tool to improve current
treatments and to rescue drugs having elevated toxicity or poor solubility. Due
to their size and surface chemistry, antimicrobial-loaded nanocarriers are
avidly taken up by macrophages, the main cells hostingMycobacterium
tuberculosis. Macrophages are continuously recruited to infected areas, they
can transport drugs with them, making passive targeting a good strategy for
TB treatment. Active targeting (decorating surface of nanocarriers with
ligands specific to receptors displayed by macrophages) further increases
local drug concentration, and thus treatment efficacy. Although in in vivo
studies, nanocarriers are often administered intravenously in order to avoid
inaccurate dosage in animals, translation to humans requires more
convenient routes like pulmonary or oral administration. This report
highlights the importance and progress of pulmonary administration, passive
and active targeting strategies toward bacteria reservoirs to overcome the
challenges in TB treatment.
1. Introduction
Mycobacterium tuberculosis (Mtb), the causative agent of tubercu-
losis (TB), has plagued humankind since antiquity. Despite its
long history, TB is currently one of the top 10 causes of death
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worldwide and the deadliest infectious dis-
ease, ranking above human immunode-
ficiency virus infection and acquired im-
mune deficiency syndrome (HIV/AIDS).[1]
In 2018, an estimated 10 million people de-
veloped TB and 1.5 million died from the
disease (including 251 000 deaths among
HIV-positive), which is equivalent to a stag-
gering 4000 deaths per day.[1] According to
the last report from the World Health Or-
ganization (WHO), 23% of the global popu-
lation is latently infected with Mtb, mean-
ing that they are asymptomatic and can-
not transmit the infection.[1] However, they
have a 5–15% lifetime risk of developing ac-
tive TB disease, being this rate higher in
individuals immunocompromised by HIV
coinfection, diabetes, and undernutrition.[2]
For this reason, the incidence is much
higher in areas where many of these condi-
tions coincide, such as South-East Asia and
Africa (accounting for 68% of new cases).[1]
The current frontline treatment for drug-
susceptible TB includes a 2-month initia-
tion phase of isoniazid (INH), rifampicin
(RIF), pyrazinamide (PZA), and ethambutol (ETB), followed by
a 4-month continuation phase of INH plus RIF.[3,4] Treatment
success rates of at least 85% for cases of drug-susceptible TB
are regularly reported to WHO by its 194 Member States.[1] The
main reason for prescribing a combination of anti-TB drugs with
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different modes of action is to reduce the emergence of drug-
resistant strains. Yet, irregular drug supply, noncompliance to the
treatment, inappropriate drug regimens, and lack of supervision
have led to the emergence of resistant strains.[5]
Those Mtb strains resistant to the cornerstone drugs RIF and
INH are named multidrug-resistant (MDR), whereas the term
extensively drug-resistant (XDR) refers to MDRMtb strains with
additional resistance to a fluoroquinolone (such as levofloxacin or
moxifloxacin (MXF)) and a second-line injectable drug (amikacin
(AMK), capreomycin, or kanamycin). Moreover, in the last years,
several cases of strains resistant to all first- and second-line drugs
used to treat TB have been reported.[6]
During 2018, about 484 000 cases of TB were caused by strains
resistant to RIF (RR-TB), of which 78% were MDR-TB. The most
affected countries by MDR-TB were India, China, and the Rus-
sian Federation, being responsible for half of worldwide cases.
Although in the European Region the TB incidence rate fell 15%
between 2015 and 2018, the proportion of RR-/MDR-TB cases
there (30%) is higher than that in all other regions (3.1–5.4%).[1,7]
Regarding XDR-TB, an estimated 6.2% of MDR-TB worldwide
cases were XDR-TB in 2018.[1] The current therapies for MDR-
TB and XDR-TB are longer (up to 18–20 months) and require
the use of second-line drugs, which are more expensive and have
more toxic side effects than the first-line drugs. In addition, the
use of injectable drugs complicates even more the adherence to
the treatments. Hence, the treatment success rate reported in
2018 was 56% for RR-/MDR-TB and 39% for XDR-TB, making
drug-resistant TB a threat to global public health.[1,8] Moreover,
TB treatment in patients with HIV is further complicated by sig-
nificant drug–drug interactions between anti-TB drugs and an-
tiretroviral therapies.[9]
Bedaquiline (BDQ, 2012), delamanid (2014), and pretomanid
(2019) are the only three anti-TB drugs with novel mechanisms
of action approved for the treatment of MDR-/XDR-TB in the
last 40 years. There are several regimens for MDR-/XDR-TB un-
der clinical evaluation which include them, such as the NiX-TB
trial. This all-oral regimen, recently approved by the Food and
Drug Administration (FDA), consists of a combination of BDQ,
pretomanid, and linezolid during 6 months for the treatment of
XDR-TB and some MDR-TB cases and led to a favorable out-
come, however associated toxic effects were observed. The lat-
est WHO guidelines on drug-resistant TB treatment suggest that
most RR-/MDR-TB patients can be treated with fully oral reg-
imens, using injectable agents (specifically AMK) only if other
options are not possible.[1,8,10,11]
Based on these, there is an increasing need for more effec-
tive therapies with less toxicity and shortened treatment duration.
Nanotechnology offers several advantages to overcome the limi-
tations of current TB therapy.[12] With the aid of this versatile ap-
proach, a sustained and targeted drug delivery can be achieved
with the promise of an efficient pulmonary administration to
further enhance treatment success.[13] The present progress re-
port provides an overview of the potential use of nanotechnology-
based drug delivery toward overcoming the challenges in TB
treatment with more emphasis on pulmonary delivery. This re-
port highlights the importance and advances of both passive and
active targeting of nanocarriers toward bacteria reservoirs in or-
der to eradicate TB. Finally, this report gives an outlook of the
progress of these systems in clinical translation.
2. TB Pathogenesis at a Glance, Know the Enemy
Mtb is an obligate intracellular pathogen, whose unique reser-
voirs are humans. Mtb infection initiates when the bacilli reach
the lungs by inhalation of aerosolized droplets expelled from
individuals with active pulmonary TB (e.g., by coughing or
sneezing). Once in the alveolar space, bacteria are internal-
ized via phagocytosis by alveolar macrophages (AMs), as the
frontline cells of the innate immune response. The pattern-
recognition receptors (PRRs) present on host cells recognize
pathogen-associated molecular patterns (PAMPs) found on the
surface of the bacilli, inducing the secretion of cytokines and
chemokines that leads to the recruitment of additional phago-
cytic cells (neutrophils, interstitial macrophages, and dendritic
cells) into the site of infection.[14,15] Following phagocytosis, in
≈20–25% of cases, macrophages can fully contain the infec-
tion and completely eliminate the pathogen,[16] however, in most
cases, Mtb manages to escape eradication by host cells.[17] Mtb
resides in the phagosome and through the activity of its ESX-
1 secretion system releases proteins and other molecules to the
phagosome, causing the disruption of the phagosomal mem-
brane and subsequently, the release of mycobacterial compo-
nents into the macrophage cytosol. As a consequence,Mtbman-
ages to arrest phagosome maturation by preventing lysosome
fusion; then, Mtb transforms the highly hostile conditions of
the phagosome into a milder environment where it can survive
and is able to replicate inside the macrophage.[18,19] Meanwhile,
infected cells migrate to pulmonary lymph nodes, where they
process and present antigens for T cell priming (both CD4+
and CD8+). After 15–18 days of Mtb infection, the adaptive
immune response produces primed T cells, which migrate to
the site of infection guided by the chemokines produced by in-
fected cells.[20] As a result, the pathogen can 1) be eliminated by
host immune response, 2) progress to active disease (mainly in
immunocompromised hosts), or 3) persist in structures called
granulomas – the pathological hallmark of tuberculosis.[18] A
granuloma is a well-organized aggregate of immune cells that
arises in response to a persistent stimulus. Granulomas are or-
ganized in spherical structures with infected macrophages in
the middle, surrounded by neutrophils, dendritic cells, natural
killer cells, B and T lymphocytes, fibroblasts, and other matrix
components.[21] Macrophages within the granulomas can differ-
entiate into other cell types, such as epithelioid cells, foamy cells,
and multinucleated giant cells, formed after fusion of multiple
macrophages.[22,23]
The main function of the granuloma is to localize and con-
fine the infection while concentrating the immune response to
a certain area. In these structures, the bacilli are exposed to a
variety of stressful conditions, such as hypoxia, acidic pH, low
iron availability, and nutrient deprivation.[24] In order to over-
come these challenging host immune responses, the bacteria
have evolvedmechanisms tomaintain viability with limited or no
replication. This state (called dormancy) is characterized by low
metabolic activity and a change in the composition and spatial
architecture of the cell wall[25] and consequently, bacteria show
phenotypic drug tolerance to antibiotics targeting functions re-
quired for growth.[26] Therefore, granulomas establish a dynamic
balance between host defenses and bacterial dormancy. If the
immune system controls the infection in granulomas, then the
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individual has latent TB infection (LTBI). LTBI is a controlled
asymptomatic and noncontagious infection that is established in
65–75% of cases[1,27] and this stage can last for years or even for
life. During LTBI, solid granulomas prevail, which are typically
encircled by a fibrotic wall that separates it from the surround-
ing tissue.[17] However, due to a dysregulation in the immune
response, dormant bacteria can reactivate leading to necrosis of
infected macrophages. This causes the formation of a necrotic
zone in the center of granulomas (known as caseum because of
its milky appearance), which contains extracellularMtb released
by necrotized foamymacrophages. Caseous necrosis – a hallmark
of pulmonary TB pathology – is associated with reduced vascular-
ization of the lesion (hypoxia) and high lipid content, as a result
from the death of foamy macrophages.[17,28] Further loss of gran-
uloma integrity allows the entry of vascular oxygen and nutrients,
which promotes the growth of the bacteria. Finally, the collapse
of the granuloma releases the bacteria to blood capillaries and
the alveolar space and disseminates to other parts of the lung
and also to other organs (hence producing extrapulmonary tu-
berculosis), in order to fully develop an active disease (meaning
that they present clinical symptoms) and also to be transmitted
to other individuals.[1,17–19,29]
2.1. Main Host Cells
BeingMtb an obligate intracellular pathogen, the range of differ-
ent type cells that it can infect is highly diverse, including both
from myeloid and lymphoid origin. Upon entry into the lungs,
Mtb is engulfed by AMs, which are the dominant cell type that
the pathogen infects; other cell types that can be infected byMtb
are interstitial macrophages and dendritic cells. In all these cases,
infection is mediated through recognition by PRRs expressed
by host cells, as described above. Other cell types that can host
Mtb intracellular replication include foamy macrophages, ep-
ithelioid macrophages, neutrophils, lymphocytes, and myeloid-
derived suppressor cells.[18,19]
It has been described that Mtb can also infect human and
micemesenchymal stem cells (MSCs), a type of multipotent cells
that can differentiate into multiple cell phenotypes. After MSCs
phagocyte Mtb mediated by scavenger receptor-A (SR-A), these
cells activate autophagy and nitric oxide production in order to
kill replicatingMtb; however, dormantMtb cannot be eliminated,
so when MSCs migrate to bone marrow, Mtb will reach a new
niche to persist. In fact, in patients that have completed success-
fully an anti-TB treatment,Mtb still can be found in CD27+ bone
marrow MSCs.[30,31]
2.2. Main Challenges for TB Treatment
Altogether, TB infection is a dynamic process in which differ-
ent pathological stages of granulomas coexist (solid, caseous, and
cavitary granuloma), so the bacilli must adapt to a variety of mi-
croenvironments to survive. Eradication of dormant bacteria is
challenging due to their tolerance to TB drugs and the suboptimal
drug concentrations reached in the caseum of necrotic granulo-
mas. Consequently, nonreplicating bacteria may serve as reser-
voirs for TB reactivation and emergence of drug resistance. In
addition, a situation similar to LTBI may occur after a drug-based
treatment of active disease, when the bacteria are not fully elim-
inated and those few that are still present in the body can be
maintained in a latent condition that may result in relapse after
a period of time.[1,27] These factors also help to explain the long
duration of TB treatments required to cure active TB. Therefore,
to successfully eradicate the infection, it has high priority to reach
the bacteria in its host cells inside granulomas.
3. Nanotechnology-Based Drug Delivery Systems
Using nanocarriers in drug delivery is an emerging strategy in
the combat against various diseases. The main advantages of
nanocarrier systems over free drugs are enhanced bioavailabil-
ity, protection of the entrapped drug from inactivation, sustained
and controlled drug release, and the possibility of reducing the
administered doses, and thus the related side effects and admin-
istration frequency. To reach the reservoirs of Mtb, a variety of
nanocarriers have been developed, including polymeric nanopar-
ticles, nanocapsules, micelles, dendrimers, nanogels, liposomes,
solid lipid nanoparticles, inorganic nanocarriers, etc. Therapeu-
tic agents can be incorporated into nanocarriers either by physical
encapsulation, adsorption, or chemical conjugation. Importantly,
using nanocarriers, it is possible to target host cells either by pas-
sive accumulation or by active targeting.[12,32]
3.1. Administration Routes of Nanocarriers for Treating TB
The different routes for nanocarrier administration have differ-
ent limitations depending on the biological environment and bar-
riers that nanocarriers face with. In TB treatment, oral, intra-
venous, topical, and pulmonary delivery of nanocarriers could be
promising. Nanocarrier characteristics can be tailored for the de-
sired delivery route in order to achieve the highest efficiency. Fig-
ure 1 represents the targeting of infected AMs and granulomas
by nanocarriers administered via different routes.
The preferable administration of nanocarriers is the oral route
as it is noninvasive and more convenient for the patients to
bring the treatment to completion. However, the harsh condi-
tions found in the gastric medium – low pH and highly prote-
olytic media – and the hepatic first-pass metabolism limit the
possible formulations and result in reduced bioavailability.[33]
Intravenous administration avoids the first-pass metabolism, it
allows drugs to be rapidly absorbed directly into the systemic
circulation and it provides a more precise control of adminis-
tered dose. The fate of intravenously injected nanocarriers is
governed by protein association (protein corona)[34] and clear-
ance by themononuclear phagocyte system (MPS). Both oral and
intravenous routes are associated with systemic side effects.[35]
The noninvasive topical route allows sustained release, local ac-
tion, thus less systemic side effect and bypass of the hepatic
first-pass metabolism. It could be favorable in case of cutaneous
tuberculosis, which is a rare condition, therefore this route is less
explored.[13,36]
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Figure 1. Targeting of alveolar macrophages and granulomas by nanocarriers administered via different routes.
Being the lung the main infected organ of pulmonary TB,
its direct targeting with pulmonary administration provides the
most promising approach in TB treatment. It further allows
to achieve a more efficient therapy with lower administration
doses and a consequent toxicity reduction as compared with
the oral route.[13,37] Pulmonary administration is promising in
case of anti-TB drugs that have limited potential if delivered
orally, since they have low water solubility, low biodistribution,
and exhibit significant side effects. Highly improved bioavail-
ability also encourages the use of the pulmonary route since
the drug-metabolizing enzyme activity is limited compared to
other organs (gastrointestinal tract and liver).[13] Moreover, it can
promote patient compliance since it is noninvasive and can be
self-administered.[38] However, the organization and physiology
of the respiratory system also contribute toward defense from
pathogens. Thus, overcoming the biological and anatomical bar-
riers in the respiratory tract can present challenges.[39]
The airways of the human respiratory system are lined with
different cell types (epithelial, ciliated, goblet, secretory, and basal
cells) with specialized functions. The major cell types of the air-
ways are epithelial cells forming amonolayer with a gradual thin-
ning from the bronchi of the upper airways to the alveoli. Themu-
cus, a continuous layer covering the respiratory tract represents a
protective coating, it is comprised of inorganic salts, proteins, gly-
coproteins (mucins), lipids, and water. The pulmonary surfactant
layer lines the alveolar epithelium and contains phospholipids,
cholesterol, and proteins. These layers affect particle dissolution,
diffusion, and interaction between therapeutic agents, cell sur-
faces, and receptors, and they are responsible for the clearance of
particles from the lungs.[40]
Alveoli, the terminating ends of all airway passages, form the
functional tissue of the lung where the gas exchange occurs. The
alveolar epithelium has a cellular component represented by in-
terstitial cells, smooth muscle cells, epithelial cells (squamous
type I and cuboidal type II), dendritic cells, and AMs and a con-
nective part that includes elastic fibers, type I collagen. The sys-
temic absorption promoted by the presence of this highly vas-
cularized architecture can decrease the local concentration of
drugs, thus this aspect could be useful to treat also extrapul-
monary TB.[13,40] Mtb mainly resides in infected AMs or granu-
lomas, therefore, alveoli represent the main target site of anti-TB
therapeutics.
Beside the presented biological barrier, the deposition of in-
haled therapeutics in the airways represents another obstacle in
reaching the target cells. The deposition of aerosolized nanocar-
riers depend on their physicochemical properties, such as parti-
cle size, aerodynamic size, and size distribution, shape, density,
and electrostatic charge.[13,40] Among them, particle size plays
the most important role in achieving deep lung deposition. The
inhaled particles should be small enough to avoid deposition
in the upper airways by sedimentation or impaction and capa-
ble of avoiding the mucociliary clearance, but they should also
avoid loss by exhalation. In general, it has been stated that large
microparticles (aerodynamic diameter between 5 and 30 µm)
deposit in the oropharynx, trachea, and bronchi for inertial
impaction, smaller ones, from 1 to 5 µm, can reach the lower
airways and can be efficiently taken up by macrophages but they
tend to form aggregates due to improper aerodynamic properties
and are subjected to mucociliary clearance. Finally, particles with
a size lower than 1 µm are capable of reaching the alveoli through
Brownian diffusion but they may be exhaled before their deposi-
tion into lungs, because of their low inertia.[41,42] To guide the
nanocarriers along the upper respiratory airways, devices, such
as dry powder inhalers, pressurized metered-dose inhalers, and
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nebulizers, may provide a breakthrough as an alternative thera-
peutic approach.[13,37,40]
3.2. Passive Targeting
Passive targeting refers to the favored distribution of the drug de-
livery nanocarrier to the area of interest without needing the func-
tionalization with ligands specific for receptors characteristic of
that area. In the case of TB, there are twomain strategies that have
been used to attain passive targeting. In the first strategy, we can
take advantage from the fact that macrophages, monocytes, and
dendritic cells, as members of the MPS, take up nanoparticles
avidly by phagocytosis or endocytosis. This issue, which is usu-
ally a problem for other applications (e.g., tumor therapy), is ben-
eficial in the case of treating infectious diseases, as immune cells
are continuously recruited to the areas of infection, particularly to
granulomas. In addition, nanocarriers can be tailored for reach-
ing enhanced uptake by MPS varying their characteristics (size,
charge, rigidness, shape). For example, it is known that positively
charged nanoparticles are more avidly taken up by macrophages
than anionic particles, since cells are slightly negatively charged.
The internalization routes will differ attending to the proper-
ties of each system, e.g., phagocytosis or endocytosis.[43] Protein
corona accumulation, opsonization, also promotes phagocytosis
by MPS.[34] Nanocarriers that are taken up by macrophages, are
transported then to the infected area.[44,45]
The second strategy resembles the controversial enhanced per-
meation and retention (EPR) effect by which, as a consequence
of their size, accumulation of nanocarriers is favored within the
tumor microenvironment compared to other areas. This supe-
rior permeation of nanocarriers arises from the rapid growth of
tumor cells which implies an angiogenesis process in which a
less-defined vasculature with pores and cavities with nanometric
size is produced. This phenomenon however has been set in high
controversy, since it was postulated as the main driving force to
produce nanoparticle accumulation in the tumor microenviron-
ment, but only modest values of accumulation have been gener-
ally observed.[46] It has been suggested that EPR could take place
in bacteria-infected tissues since inflammatory reactions also re-
sult in increased microvascular permeability of the capillaries.[47]
Therefore, in principle, it would be possible to take advantage of
this phenomenon to enhance activity of nanoparticles at infec-
tion sites, such as a granuloma. To do so, nanoparticles with long
circulation times would be preferred so that they are more likely
to accumulate in this area.
Plenty of studies demonstrate the in vitro and in vivo achieve-
ments of using passively targeted nanocarriers against TB as re-
viewed recently.[12,13,48–54] Most in vitro experimental models of
TB infection for studying effects of nanocarriers use primary
macrophages, macrophage-like immortalized cell lines, and in-
duced pluripotent-stem-cell-derived macrophages. In vitro gran-
uloma model based on human peripheral blood mononuclear
cells (PBMCs) represents a more complex system.[55] Animal
models for TB are mice, guinea pigs, rabbits, nonhuman pri-
mates, and zebra fish (adult and larvae).[56]
Some recent studies applying nanocarriers via passive target-
ing through nonpulmonary administration are summarized in
Table 1.
To illustrate the state of the art in the field of TB nanoth-
erapeutics we have selected one example that covers all the
steps from the polymer design, nanoparticle characterization to
in vivo evaluation. Trousil et al.[45] prepared block copolymers
based on hydrophilic poly(ethylene glycol) (PEG) and hydropho-
bic poly(caprolactone) (PCL) blocks, with different hydrophilic
to hydrophobic ratio and molecular weights. These amphiphilic
polymers are able to self-assemble in solution forming nanopar-
ticles, encapsulating RIF in the inner hydrophobic core, with
good drug loadings (from 10% to 23%). PCL is a biodegradable
polyester that undergoes slow hydrolysis catalyzed by lipases in
physiological conditions. Although lipase may favor the drug re-
lease, in the hydrolysis and release study, it was found that the
release process was driven by diffusion from the nanoparticle
core. The first step in the biological characterization attended to
cell viability and internalization rate in the murine monocyte–
macrophage Raw 264.7 cell line. The plain nanoparticles had no
cytotoxic activity. However, encapsulated RIFwasmore toxic than
the free drug, what can be correlated with an enhanced uptake
favored by the encapsulation of the drug. The hydrophilic to hy-
drophobic ratio drove the uptake rate: particles with higher hy-
drophilic content were internalized to a greater extent which was
ascribed to be less prone to develop a thicker protein corona.
Among all nanoparticles, the authors selected only one, that
gathered great colloidal stability, appropriate size (75 nm with
4:6 hydrophobic to hydrophilic ratio), and good in vitro perfor-
mance (cell internalization and degradability). The general an-
tibacterial properties of the nanoformulation were studied using
several bacterial strains. The selected nanoparticle resulted in a
1.3-fold to sixfold reduction of the minimal inhibitory concentra-
tion (MIC) depending on the bacterial strain, which suggested
that the polymer was capable of permeating the bacterial mem-
brane. Macrophages infected with Mtb H37Rv strain were sub-
sequently evaluated as a more complex model to study toxicity
and internalization of the nanoformulations. After 48 h incuba-
tion with the nanoparticles, the authors observed that the encap-
sulated drug was just slightly more active than the free drug.
However, they extended the experiment up to 5 days and found
that when treated with free RIF, the infection persisted, while it
was completely eradicated when the drug had been previously
encapsulated. Based on that, the RIF-free nanoparticles also had
some activity in the infected macrophage experiments, the au-
thors proposed that the amphiphilic structure of the polymer in-
teracted with the mycobacterial wall, sensitizing bacteria against
the internal elimination mechanisms of macrophages. Finally,
the in vivo antimicrobial activity was studied in zebra fish em-
bryos infected by injection withMycobacterium marinum. The ex-
periments were performed with a single injected dose the day
after infection. The mortality in the infected group treated with
RIF was delayed for about 3 days compared with the untreated
infected group. However, the survival rate was 0% after 9 days.
By contrast, the administration of encapsulated drug led to an
outstanding 50% survival rate 9 days after infection.[45] The phar-
macokinetics, pharmacodynamics, and anti-TB efficacy of the
nanoformulated RIF were further assessed in a mouse model
(BALB/c mice infected intranasally with Mtb H37Rv) as a clin-
ically relevant in vivo model.[64] Biodistribution study revealed
that the nanoparticles were found mainly in the liver and in in-
testinal tissue, i.e., macrophage-rich organs. The nanoparticles
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Table 1. Summary of some recent contributions of nanocarriers via passive targeting in TB treatment – in vitro and in vivo studies through nonpulmonary
administration.
a)
Nanocarrier Loading Key findings Ref.
PLGA nanoparticles (NPs) RIF, coumarin-6 Enhanced activity on intracellular bacteria (BMDM infected with
Mycobacterium bovis BCG) compared to free drug; NPs remained
membrane-bound in phagolysosomes in RAW 264.7 cells
[57]
PLA–PEG polymeric micelles INH (conjugated), RIF Loaded micelles were less hemolytic and had lower MIC values on
Mtb than free drugs
[58]
PLGA NPs, alginate-coated or
-entrapped
AMK, MXF Coencapsulation of AMK and MXF performed better than each drug
separately in inhibitingMtb H37Ra; efficient uptake in dTHP-1 cells;
slower release in phosphate buffered saline solution
[59]
Chitosan nanocapsules and lipid
NPs (soybean lecithin,
DOTAP, PEG 40 stearate)
BDQ Nanoformulations had similar MIC as free drug againstMtb H37Rv;
low or no cytotoxicity on dTHP-1, A549 and HepG2 cells; high





BDQ Enhanced antimicrobial activity againstMtb H37Rv compared to free





RIF Microparticle formulation protected the NPs from degradation under
simulated gastric conditions; enhanced activity inMtb-infected
MH-S cells; NPs were able to cross the in vitro model of intestinal
barrier
[62]
PLGA NPs RIF, thioridazine (TZ, a
bacterial efflux pump
inhibitor)
Encapsulation reduced toxicity of TZ in macrophages (BMDM and
human monocyte-derived macrophages) and in zebra fish (Casper,
Tg); enhanced therapeutic effect inMycobacterium marinum-infected





RIF Cytotoxicity on RAW 264.7 cells; enhanced MICs on different bacterial
strains; enhanced activity against intracellular bacteria (RAW 264.7
infected withMtb H37Rv); NPs were not toxic and were more
efficient inM. marinum-infected zebra fish; high anti-TB efficiency








Rapid, high-level accumulation in monocytes and neutrophils, and
less efficient uptake by B and T cells in human PBMC; colocalization
withMtb H37Rv in phagosomes of dTHP-1; inM. marinum-infected
zebra fish model NPs were taken up by macrophages; NPs had
better activity in reducing bacterial burden and granuloma number
[65]
PLGA NPs, other type of NPs RIF, several fluorescent dyes Rapid NP uptake by macrophages and lowered bacterial load inM.
marinum-infected zebra fish model; NP accumulation in
granulomas in zebra fish model and in C57BL/6 mice (intranasally
infected withMtb) following intravenous administration
[66,67]
Niosomes (Span 60, Span 85,
cholesterol, dicetyl phosphate,
stearylamine)
ETB Sustained release of drug in Swiss albino mice lungs after
subcutaneous injection of niosomes; enhanced efficiency in
decreasing bacterial counts in lung of guinea pigs (infected by
intramuscular injection ofMtb H37Rv) after subcutaneous injection
[68]
PLGA NPs Ethionamide (ETH) Enhanced bioavailability of NPs when administered orally compared
to free drug; ETH detected in lung, liver, and spleen, and no toxic







Orally administered STR NPs were as effective as subcutaneously
injected aqueous STR solution in a chronic infection mouse model
(BALB/c mouse infected with aerosol ofMtb psmt-Erdman strain)
[71]
Poly(caprolactone) (PCL) NPs ETB, 99mTc for imaging NPs were as effective against intracellular bacteria as free ETB inM.
bovis BCG-infected J774A.1 cells; NPs reached the lung following
intraocular injection in mice infected byM. bovis BCG through the
thoracic cavity
[72]
a)Abbreviations: MIC: minimal inhibitory concentration; PLGA: poly(lactic-co-glycolic acid); A549: human lung alveolar epithelial cell line; BCG: Bacillus Calmette-Guérin;
BMDM: murine-bone-marrow-derived macrophages; dTHP-1: differentiated human macrophage-like cells; HepG2: human liver epithelial cell line; J774: murine macrophage
cell line; MH-S: murine alveolar macrophages; PBMC: human peripheral blood mononuclear cells; RAW 264.7: murine macrophage cell line; PEG: poly(ethylene glycol);
DOTAP: 1,2-dioleoyl-3-trimethylammoniumpropane.
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were well tolerated, compared to free RIF, RIF-loaded nanopar-
ticles showed improved pharmacokinetic and pharmacodynamic
parameters with higher serum and lung RIF level. Both free drug
and drug-loaded nanoparticles reduced the bacterial burden in
both lung and spleen after treatment with intraperitoneal admin-
istration. Importantly, the treatment with drug-loaded nanoparti-
cles was preferred as significantly less granulomas were observed
compared to the treatment with the free drug.[64]
Zebrafish larvae have emerged as a vertebrate animal model
since they gather unique characteristics like transparency, ease
of manipulation, an innate immune response, and high degree
of similarities with human genome. Importantly, granulomas
formed in M. marinum-infected zebra fish model resemble hu-
man Mtb granulomas to a greater extent than that of the Mtb in
a mouse model.[73,74] These features permit to generate a robust
model to screen nanocarriers before going tomore complexmod-
els likemammals, that involve further ethical considerations. The
Griffith group has used this in vivo model for studying anti-TB-
drug-loaded liposomes and polymeric nanoparticles.[66,67,75] They
showed that intravenously injected poly(lactic-co-glycolic acid)
(PLGA) nanoparticles were internalized by both infected and
uninfected macrophages in the zebra fish larvae. Nanoparticle-
containing uninfected macrophages could subsequently migrate
to the granulomas providing an efficient targeting. RIF-loaded
nanoparticles significantly increased survival and lowered bac-
terial load.[66] In order to evaluate the possible EPR effect in
granulomas in infected zebra fish larvae, Fenaroli et al.[67] in-
jected M. marinum in the neural tube of zebra fish instead of
intravenously. This protocol for the infection, which had been
introduced previously by Oehlers et al., allowed the formation
of well-defined granulomas compared to less defined dynamic
structures observed after intravenous injection.[76] The studied
liposomes and nanoparticles, covered with stealth-like polymers
(PEG or poly(sarcosine) (Psar)), crossed the endothelial barri-
ers near infection sites within minutes after injection and accu-
mulated close to granulomas. They found that the vasculature
increased notoriously in the surrounding area of the granulo-
mas in the neural tube, supporting this idea of the augmented
vascularity.[76] In mice infected intranasally with Mtb, they ob-
served the same preferential accumulation of PEG–liposomes
and Psar micelles in the granuloma showing that the zebra fish
model can be used to predict nanoparticle behavior in mam-
malian hosts.[67] Furthermore, the pharmacokinetics of lipo-
somes and nanoparticles (circulation time, interactions with key
target cells, macrophages, and endothelial cells) are similar in ze-
bra fish and mice models according to a recent study carried out
by Dal et al.[75]
Nanocarriers demonstrated an elevated and prolonged drug
accumulation in lung inmice compared to free drugs when intra-
venous or subcutaneous administration was used.[67,68] However,
direct pulmonary administration further enhances the bioavail-
ability in lungs that favors the efficacy of the treatment and de-
creases the systemic adverse effects. Nanocarriers are regularly
embedded in microparticles (1–5 µm) to achieve formulations
with appropriate size for facilitated deep lung delivery. Once
reaching the alveolar region, microparticles are expected to read-
ily dissolve, delivering the nanocarriers which, in turn, are inter-
nalized by AMs and can release the encapsulated drug.[40,51,77,78]
Some recent approaches applying passively targeted nanocar-
riers for pulmonary administration route are summarized in
Table 2.
In a recent example for pulmonary delivery, Gaspar et al.[89] de-
velopedmicroparticles of trehalose andmannitol – two known ex-
cipients for preparing microparticles by spray drying – to encap-
sulate solid lipid nanoparticles (SLNs) that contained rifabutin
(RFB). These SLNs were prepared using two types of glyceryl es-
ters, glyceryl dibehenate and glyceryl tristearate and were covered
with Tween 80 as a surfactant, yielding sizes of≈100 and 200 nm,
respectively, with a drug loading content of 9% and 6%, respec-
tively. Spray drying the nanoparticles with trehalose or manni-
tol produced microparticles around aerodynamic diameters of 4
and 5 µm which are in the optimal size range for lung deposi-
tion. These excipients are readily soluble in water, so when the
dry powder was resuspended in buffer, containing a lung surfac-
tant, the SLNs could be recovered. The microparticulate system
developed permitted to stabilize the nanoparticle formulation. In
fact, when the drug release from the microparticles was evalu-
ated, the authors concluded that despite the initial burst release,
RFB followed a steady release over 24 h. The in vivo biodistri-
bution study in mice after inhalation demonstrated that the mi-
croencapsulated RFB–SLN provided higher amounts of RFB in
lung when compared with plain RFB in mannitol microspheres.
In accordance with the literature, the inhaledmicroparticles were
able to reach systemic circulation, thus liver and spleen. The in-
haled drug-loaded formulation efficiently reduced the bacterial
burden in lung, spleen, and liver ofMtb-infected mice (infection
induced by intravenous injection of bacteria).[89]
In view of the publications reviewed during this section, we
can conclude that passive targeting is a powerful tool to be con-
sidered when designing nanoparticles for drug delivery in in-
fectious diseases, in particular in TB. This success relies on
the accumulation of nanocarriers in granulomas by the recruit-
ment of macrophages that phagocytosed the nanocarriers or
via an alternative process that resembles EPR. The possibil-
ity of direct pulmonary delivery of nanocarriers raises further
promises.
3.3. Active Targeting
Active targeting is now a key approach to direct more effectively
drug-loaded nanocarriers toward the presented habitat of Mtb
and to achieve enhanced specificity. Active targeting relies on
the interaction between specific ligands on the surface of the
nanocarriers and the receptors of the target cells. In many cases,
this approach leads to receptor-mediated endocytosis, thereby,
the intracellular drug concentration in target cells further in-
creases. In the case of TB, to increase significantly the speci-
ficity of anti-TB-drug-loaded nanocarriers, we can take advan-
tage of characteristic receptors of MPS cells as main host cells.
Therefore, PRRs of phagocytes are straightforward candidates
as target receptors. These receptors are responsible for sens-
ing the presence of microorganisms by recognizing microbial
PAMPs and consequently this interaction leads to the internal-
ization of the pathogen. There are several subgroups of PRRs.
They are classified according to their ligand specificity, func-
tion, localization, and evolutionary relationships. Based on their
Adv. Therap. 2020, 2000113 © 2020 The Authors. Published by Wiley-VCH GmbH2000113 (7 of 22)
www.advancedsciencenews.com www.advtherap.com
Table 2. Summary of some recent in vitro and in vivo contributions of nanocarriers aiming passive targeting in TB treatment through pulmonary
administration.
a)
Nanocarrier Loading Key findings Ref.
Superparamagnetic iron oxide




Multifunctional microparticulate dry powder with magnetic
responsiveness; drug release is tuned by alternate magnetic fields;
no cytotoxicity on L929, BMDM, and dTHP-1 cells
[79]
PLGA microspheres Degradex near-infrared
fluorescent dye
Comparison of inhalation techniques: oropharyngeal aspiration and
intratracheal instillation using Microsprayer Aerosolizer or BioLite
Intubation System in Swiss Webster mice; oropharyngeal aspiration
showed microsphere deposition in the oral cavity; intratracheal
instillation techniques resulted in the most efficient deposition in
the lungs
[80]
Chitosan NPs, lactose preblend BDQ Dry powder formulation; no cytotoxicity on J774 cells; no toxicity in
Wistar rats, highest accumulation in lungs, least concentration in
blood as compared to inhaled free BDQ or orally administered BDQ
solution
[81]
Poly(𝛽-cyclodextrin) NPs ETH and its booster Coencapsulated formulation had improved activity against
intracellular bacteria on RAW 267.4 cells infected withMtb H37Rv;
effective reduction of bacterial burden with subtherapeutic doses in
BALB/c mice (intranasally infected withMtb H37Rv) after
intratracheal aerosol administration (Microsprayer)
[82]
Chitosan NPs, mixed with
lactose
Prothionamide (PTH) Better pharmacokinetic profile than free PTH; maintained drug
concentration in lungs above MIC after administration of
formulation with dry powder inhaler delivery device via intratracheal
route in Wistar rats
[83]
Chitosan NPs, mixed with
mannitol and leucine
RIF, INH Coencapsulated dry powder formulation showed increased
bioavailability for both drugs in lungs, and other macrophage-rich
organs (spleen, kidney, liver); effective reduction of bacterial level
after pulmonary administration with a compressor nebulizer system




STR sulfate Lower systemic (nontarget organ) drug exposure compared to
intramuscular injection and higher local drug accumulation





INH, RIF, PZA Coencapsulated formulations had enhanced bioavailability compared
to oral and intravenous administration of free drugs; it had
sustained therapeutic drug levels in plasma and lungs; no
hepatotoxicity was observed, after pulmonary administration (face
mask connected compressor nebulizer system); no detectable
bacterial load was observed in the lungs of infected guinea pigs
(Dunkin Hartley, infected intramuscularly withMtb H37Rv); it
allowed reduced dosing frequency compared to oral administration
[86–88]
Solid lipid nanoparticles (SLNs)
in trehalose or mannitol
microparticles
RFB SLNs could be recovered in lung surfactant containing buffer;
enhanced lung accumulation in BALB/c mice following dry powder
inhalation; NPs could reach also liver and spleen; efficient reduction
of bacterial burden in lung, spleen, and liver of infected mice
(infected intravenously withMtb H37Rv)
[89]
a)Abbreviations: L929: mouse fibroblast cell line; BSA: bovine serum albumin.
localization in the cell, PRRs are divided into two main groups:
membrane-bound PRRs, such as Toll-like receptors (TLRs) and
C-type lectin receptors (CLRs), and cytoplasmic PRRs, such as
nucleotide-binding oligomerization domain (NOD)-like recep-
tors and retinoic acid-inducible gene I (RIG-I)-like receptors. For
receptor targeting, membrane-bound PRRs have a greater impor-
tance. TLRs can recognize mainly lipopolysaccharides, lipopro-
teins, heat shock proteins, and flagellar proteins, while CLRs have
specificity for carbohydrate derivatives expressed on the surface
of microbes (e.g., mannose, fucose, 𝛽-glucans, glycolipids).[90–93]
The scavenger receptor superfamily, a subset of membrane-
bound PRRs, is also a promising candidate for targeted drug
delivery since they are highly expressed on macrophages. Scav-
enger receptors can recognize a broad variety of ligands, such
as polyionic molecules including oxidized lipoproteins, phos-
pholipids, proteoglycans, polysaccharides, and components of
Adv. Therap. 2020, 2000113 © 2020 The Authors. Published by Wiley-VCH GmbH2000113 (8 of 22)
www.advancedsciencenews.com www.advtherap.com
Figure 2. Drug delivery strategies to targeting infected macrophages with a schematic summary of macrophage receptors that can be used for active
targeting.
bacteria.[94] Scavenger receptors play an important role in the
clearance function of AMs.[95] Besides the PRRs, Fc receptors
(FcR) and complement receptors (CRs) are two main phagocyte
receptors and they are responsible for opsonin-dependent phago-
cytosis and different immune responses leading to the clearance
of the opsonized pathogen. FcRs recognize the Fc fragment of an-
tibodies, while CRs recognize complement proteins that are en-
gaged in pathogen opsonization.[93,96,97] Figure 2 represents the
concept of active targeting of nanocarriers compared to passive
targeting and the use of free drugs, and it provides a schematic
summary of macrophage receptors that can be used for active tar-
geting.
Plenty of ligands have been identified and investigated for
promoting active targeting of nanocarriers. Such targeting lig-
ands can be, among others, antibodies, proteins, peptides, carbo-
hydrates, nucleic acid aptamers, and small molecules.[98,99] De-
spite that the majority of the studies of ligand-targeted nanocar-
rier systems are focused on cancer therapy, this knowledge
can be adapted in host-cell-targeted drug delivery against in-
tracellular pathogens, such as Mtb. Specifically, macrophages,
besides being common host cells for intracellular pathogens,
are widely studied as therapeutic target cells since they are
extensively involved not only in cancer but also in inflam-
matory diseases.[100,101] In this section, achievements in the
field of host-cell-directed targeting in the treatment of TB are
highlighted.
3.3.1. Mannose Receptor Targeting
The mannose receptor (CD206) is a C-type lectin recep-
tor that recognizes ligands with a terminal mannose, N-
acetylglucosamine, or fucose moiety.[102] This receptor is ex-
pressed abundantly bymost tissuemacrophages and also by den-
dritic cells. It mediates endocytosis, phagocytosis, and also in-
flammatory signaling pathways. Moreover, it plays an important
role in the uptake of Mtb by phagocytosis, in the inhibition of
phagosome–lysosome fusion, and therefore, in the intracellular
survival of the bacteria.[102–104] In addition, the mannose receptor
also plays a role in the formation of granulomas.[102] Based on
these findings, targeting the mannose receptor is promising for
treatment of TB and intracellular colocalization of the bacteria
and the nanocarrier is more possible as they can share the same
entry pathway into the macrophages. A great number of works
have focused on targeting macrophages through their mannose
receptor and demonstrated improved uptake of the mannosy-
lated nanocarriers relative to nontargeted formulations. Different
functionalization strategies were developed for mannosylation
including the synthesis of mannose–nanocarrier building block
conjugates followed by nanocarrier formation, covalent function-
alization of the formed nanocarriers, and physical adsorption of
mannose to the surface of the nanocarriers.[105,106] Recent find-
ings on active targeting of anti-TB-drug-loaded nanocarriers via
macrophage mannose receptor are summarized in Table 3.
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Table 3. Examples of active targeting via mannose receptor in nanotechnology-based anti-TB drug delivery systems.
a)
Nanocarrier Loading Ligand, method Key findings Ref.
SLN: palmitic acid, cholesteryl
myristate
RIF Mannosylated fatty acid
derivatives
Inhalable powder; enhanced cellular uptake on J774
cells; lipid corona formation did not modify uptake
on MH-S cells; highest retention in lungs, slight
inflammatory response, low systemic biodistribution
in Swiss albino mice (intratracheal instillation)
[107–109]
SLN: Witepsol E85 (hydrogenated
coco-glycerides), stearylamine,
PVA as surfactant, inner aqueous
phase
INH, coumarin-6 Stearylamine–mannose
derivative by formation of
Schiff base
Reduced cytotoxicity of INH on NCI-H441 and on
dTHP-1 cells; enhanced uptake on dTHP-1
[110]
SLN: glycerol tripalmitate,
stearylamine, Tween 80 as
surfactant
RIF, coumarin-6 Stearylamine–mannose
derivative by formation of
Schiff base
Slightly reduced cytotoxicity of RIF on dTHP-1 cells;




stearylamine, Tween 80 as
surfactant
RFB, FITC Stearylamine–mannose
derivative by formation of
Schiff base
Enhanced uptake on J774, prolonged circulation, high







Formation of amide bond
between 1-aminophenyl-
𝛼-d-mannopyranoside
and gelatin, with EDC,
NHS
No cytotoxicity on J774E; enhanced uptake on J774E;
internalization via the mannose receptor; in albino
mice (i.v. injection) organs with phagocytic cells
internalized NPs in a higher extent (liver, spleen), low
heart accumulation
[113]
NLC: Precirol ATO 5 (glyceryl
palmitostearate), miglyol-812
(caprylic/capric triglyceride),
stearylamine, Tween 60 as
surfactant
RFB, RIF, FITC Stearylamine–mannose
derivative by formation of
Schiff base
Slight cytotoxicity on lung epithelial cells (Calu-3, A529)
and macrophages (RAW 264.7, BMDM); enhanced
internalization by BMDM; more efficient restriction
of intracellular growth ofM. avium in infected BMDM
[114,115]




RIF, FITC–DHPE Mannosylated cholesterol
derivative
Enhanced uptake on NR8383 cells; low toxicity and no
inflammatory response in L929 cells; enhanced
cellular uptake by AMs in Wistar rats (i.v. injection);
no inflammatory response; superior lung targeting of
NLC compared to high RIF accumulation in liver in







Formation of Schiff base
between mannose and
amino-PEG
Good activity on extracellular bacteria; very low
cytotoxicity; enhanced uptake on dTHP-1 cells;
enhanced ex vivo cellular uptake and selectivity on
primary macrophages and intraepithelial
lymphocytes from intestinal mucosae ofMtb-infected
Rhesus monkey; mannose-receptor-mediated
endocytosis and macropinocytosis/phagocytosis,
lysosomal localization; improved activity on
intracellular bacteria in infected dTHP-1 and infected








Mannose reacted with the
amino group of chitosan
with the aid of EDC
Low cytotoxicity on dTHP-1 and HLMVEC; synergistic
activity on extracellular bacteria; enhanced uptake
and selectivity toward macrophages; enhanced ex
vivo cellular uptake and selectivity on primary
macrophages and intraepithelial lymphocytes from
intestinal mucosae of Rhesus monkey;
mannose-receptor-mediated endocytosis,
clathrin-mediated endocytosis, nanoparticles
colocalized in lysosomes withMtb; improved activity
on intracellular bacteria in infected dTHP-1 and
infected monocyte-derived macrophages from
healthy Rhesus monkey; NPs promote the fusion of
Mtb into lysosomes, enhance autophagy and
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Table 3. Continued
Nanocarrier Loading Ligand, method Key findings Ref.
Gelatin NPs (glutaraldehyde
cross-linked)
INH, FITC Formation of Schiff base
between mannose and
gelatin
Enhanced uptake on J774; effective delivery of NPs to
alveolar tissues; reduced hepatotoxicity; enhanced
anti-TB activity on BALB/c mice (intranasally infected
withMtb H37Rv) after NP i.v. injection
[119]




RIF Mannose from hydrolyzed
galactomannan











Liposomes had same MIC as free MXF on extracellular
Mtb; low cytotoxicity on A549 cells; enhanced uptake
on J774A.1 cells; mainly alveolar localization of
ungrafted formulation after intrapulmonary
administration with dry powder inhaler in albino rats
(mannosylated was not tested)
[121]
Liposomes: DSPC, cholesterol FITC–DHPE Mannosylated cholesterol
derivative
Enhanced uptake on primary rat AMs; in vivo selectivity:
higher association with AMs, rather than alveolar
epithelial type II cells in Wistar rats after intratracheal
administration
[122]






Enhanced uptake on NR8383 cells; in vivo enhanced
delivery to AMs; no pulmonary toxicity in
Sprague-Dawley rats after intrapulmonary










Cellular uptake on J774E, J774A.1 cells; determination
of optimal mannose density on the surface of
nanocarriers
[124]
Chitosan nanocapsules, Tween 20,
Span 85, oleic acid
Nile Red, DiD flurophores Trimannose ligand, BS3
cross-linker
Similar uptake of grafted and nongrafted nanocapsules
on differentiated macrophages; actin
cytoskeleton-dependent process; grafted





Amphotericin B, Nile Red Palmitoyl mannose or
4-SO4GalNAc
Enhanced uptake of 4-SO4GalNAc–liposomes
compared to mannosylated liposomes on J774A.1
and RAW 267.4 cells, no cytotoxicity on these cells;
4-SO4GalNAc strongly interacts with the cysteine rich
domain of the mannose receptor; functionalized
liposomes had higher accumulation in liver and
spleen of Wistar rats after i.v. administration
[127]
a)Abbreviations: i.v.: intravenous; NLC: nanostructured lipid carrier; A529: human bronchial epithelial cell line; Calu-3: human airway epithelial cell line; HLMVEC: hu-
man lung microvascular endothelial cells; NCI-H441: human lung epithelial cell line; NR8383: rat alveolar macrophage cell line; SLN: solid lipid nanoparticle; PVA:
poly(vinyl alcohol); FITC: fluorescein-isothiocyanate; EDC: 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide; NHS: N-hydroxysuccinimide; DHPE: 1,2-dihexadecanoyl-sn-
glycero-3-phosphoethanolamine; DSPC: 1,2-distearoyl-sn-glycero-3-phosphocholine; PS: poly(styrene); DMPC: 1,2-dimyristoyl-sn-glycero-3-phosphocholine.
Inhalable, RIF-loaded mannosylated SLNs were developed to
target AMs by dry powder inhaler device. Mannosylated fatty
acid derivatives with a dual role of functionalizing agents and
surfactants were incorporated into SLNs. The improved target-
ing ability was verified in vitro, mannosylated SLNs exhibited
higher cellular uptake rate as compared to RIF and nonfunc-
tionalized SLNs. The functionalized particles also had an ade-
quate respirability that is promising for the future use in in-
halation therapy.[107] Furthermore, using a pulmonary surfac-
tant model, it was shown that the lipid corona formed around
SLNs improved drug retention in simulated lung fluid. The pres-
ence of the lipid corona did not mask completely the functional
groups on nanoparticle surface, since the in vitro uptake rate did
not decrease significantly.[108] Importantly, in in vivo biodistribu-
tion studies in mice after intratracheal instillation, mannosylated
SLNs showed the highest retention in lungs associated with a
poor spreading in extrapulmonary regions in comparison with
both nonfunctionalized SLNs and bare RIF.[109]
Costa et al. prepared stearylamine containing SLNs using hy-
drogenated coco-glycerides as lipid components. The SLNs were
functionalized with mannose forming a Schiff base (imine) be-
tween the primary amine group of stearylamine and the alde-
hyde group of the open-chain form of mannose. These SLNs
loaded with INH were able to reduce the in vitro cytotoxicity of
INH on lung epithelial cells and macrophages. Mannosylation
enhanced the in vitro uptake of fluorescently labeled SLNs by
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macrophages.[110] Similar results were obtained with RIF-loaded
mannosylated SLNs composed of glycerol tripalmitate as lipid
component.[111]
Mannosylated SLNs composed of tristearin, soya lecithin,
stearylamine and loaded with RFB were prepared, and this for-
mulation was found to be in the highest level in lungs as com-
pared to the free RFB and the uncoated SLN in in vivo exper-
iments with rats after intravenous injection. The free RFB had
the highest concentration in the kidney and it had a rapid clear-
ance by this organ. Moreover, the study suggests that mannosy-
lation possibly helped to bypass renal elimination and that man-
nosylated SLNs are rather eliminated by the liver.[112] Other in
vivo results also confirmed that mannose coating has advanta-
geous influence on the biodistribution of nanocarriers. Gelatin
nanoparticles were internalized to a greater extent in organs with
phagocytic cells, such as liver and spleen, while low accumulation
in the heart was observed. Mannosylation further enhanced the
accumulation in liver and spleen.[113]
Nanostructured lipid carriers (NLCs) are composed of a
mixture of solid and liquid lipids, and these nanoparticles
showed enhanced drug-loading capacity compared to SLNs.
Unloaded NLCs showed a slight in vitro cytotoxicity on hu-
man airway epithelial and bronchial epithelial cell lines, and
on murine macrophages, however, mannosylated RIF-loaded
NLCs had improved cellular uptake and showed better intra-
cellular growth inhibition of Mycobacterium avium in infected
macrophages than free RIF or nonfunctionalized NLCs at non-
cytotoxic concentrations.[114,115] Other mannosylated, RIF-loaded
cationic NLCs displayed superior lung-targeting ability in vivo af-
ter intravenous administration without inducing inflammatory
response in mice and rats. Greater AM uptake of mannosylated
NLCs was observed in vitro and in vivo compared to unmodi-
fied NLCs. Furthermore, the in vivo inhibition of mannose re-
ceptor in rats by intratracheal instillation with mannan dramati-
cally decreased the uptake of mannosylated NLC, demonstrating
the involvement of the receptor in the uptake. The authors also
proposed that these cationic NLCs interact with serum proteins,
thus generating large and loose complexes which can lead to their
specific accumulation in the lung.[116]
In a recent study, mannose-surface-decorated and PEGylated
graphene oxide nanocarriers have been shown to enhance the up-
take of RIF and also remarkably improved elimination of intracel-
lular Mtb in in vitro and ex vivo models. For these nanocarriers,
the predominant cellular uptake pathways were mannose-
receptor-mediated endocytosis and micropinocytosis or
phagocytosis. The internalized nanocarriers were mainly ac-
cumulated in the lysosomes, where the acidic environment
could accelerate the release of RIF to kill the intracellular Mtb
more efficiently. Additionally, nanocarrier treatment maintained
a much higher intracellular RIF concentration in macrophages
in vitro as compared to the free drug. In ex vivo experiment
using intraepithelial lymphocyte isolated from the intestine of
Mtb H37Rv-infected Rhesus monkey, it was determined that
the nanocarrier was internalized in remarkably higher extent by
CD14+ primary macrophages, the uptake by macrophages was
nearly double than the uptake by epithelium and CD14− lympho-
cytes. This finding demonstrated the selective targeting potential
of mannosylated nanocarriers against macrophages.[117] This
group also synthesized mannosylated, chitosan-stabilized INH-
loaded selenium nanoparticles with core–shell structure. With
these nanoparticles, similar results (including enhanced cel-
lular uptake, intracellular killing of Mtb, and selectivity in in
vitro and ex vivo models due to mannosylation) were achieved.
Unloaded nanoparticles inherently inhibited bacteria and the
INH-loaded nanoparticle showed synergistic bacterial killing.
Moreover, the nanoparticles may also contribute to the innate
immunity of the infected host cells since they promote the
fusion of Mtb containing phagosomes with lysosomes, thus
synergizing the lysosomal and INH driven destruction of in-
tracellular bacteria. Furthermore, autophagy and apoptosis are
also involved in the nanoparticle-mediated intracellular antibac-
terial activity. Altogether, these nanoparticles achieved a highly
effective intracellularMtb clearance in vitro.[118]
In case of INH-loaded mannosylated gelatin nanoparticles,
effective delivery of mannosylated nanocarriers to alveolar tis-
sues was observed accompanied by reduced hepatotoxicity. Im-
portantly, these nanoparticles possessed an enhanced in vivo anti-
TB activity inMtb-infected mice.[119]
Hydrolyzed galactomannan providing mannose residues
was used as targeting moiety. RIF-loaded polymeric micelles
surface-decorated with chitosan and combined with hydrolyzed
galactomannan boosted intracellular levels of RIF in murine
macrophages.[120]
For improved physical stability and lung deposition, liposomes
loaded with MXF were embedded into microparticles using dex-
tran as a carrier by spray drying. Mannosylation of the liposomes
remarkably enhanced the in vitro uptake by AMs. The in vitro
anti-TB activity of MXF was preserved in the formulations. Deep
lung deposition was confirmed in rats by intrapulmonary admin-
istration using a dry powder inhaler. However, it was not tested
with the mannosylated formulation.[121]
Wijagkanalan et al. demonstrated in vivo the efficient target-
ing of mannosylated liposomes via mannose-receptor-mediated
endocytosis to AMs by intratracheal administration in rats. The
liposomes had selective targeting ability, although both bare
and mannosylated liposomes were preferentially associated with
AMs, the mannosylated liposomes showed extensive uptake by
AMs, rather than by alveolar epithelial type II cells.[122] Similarly,
Chono et al. also found that mannosylated liposomes were more
efficiently delivered to AMs than nonmodified liposomes after
pulmonary aerosolization and liposomes did not harm the lung
tissues of rats and were biocompatible in lung. They showed that
the in vitro uptake of mannosylated liposomes is saturated with
the increase of the surface mannosylation rate.[123] Other studies
also showed that there is an optimal mannose density on the sur-
face of nanocarriers for the maximum targeting and uptake by
mannose receptor.[124] Optimal mannose units per nanocarrier
building blocks and distance between adjacent mannose units
are also important aspects for the efficient mannose-receptor-
mediated endocytosis.[125]
In addition to targeting, mannosylation can have an impact
on macrophage response as it was found in case of trimannose-
grafted chitosan nanocarriers. These nanocarriers remodeled the
macrophage response to bacterial infection, in particular affect-
ing the regulation of many metabolic pathways including oxida-
tive phosphorylation and sugar metabolism.[126]
A new mannose receptor targeting strategy was proposed
with an alternate approach. A sulfated sugar ligand (4-sulfated
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Table 4. Examples of active targeting via folate receptor in nanotechnology-based anti-TB drug delivery systems.
Nanocarrier Loading Ligand, method Key findings Ref.
Nanocapsules: oleic acid, Tween 80
(emulsifier), ethanol (drug cosolubilizer),
chitosan oligosaccharide lactate
RIF, FITC Folic acid conjugated to
chitosan, with EDC
No cytotoxicity, enhanced uptake on NR8383 cells;
aerosolization (Omron nebulizer), higher lung drug
content; reduced plasma drug concentration in
Sprague-Dawley rats after intrapulmonary
administration using Microsprayer aerosolizer
[137]
Liquid-crystalline folate nanoparticles
(self-assembled structure), NaOH, CaCl2,
ZnCl2, hydroxypropyl methyl-cellulose
RIF Folic acid-based nanocarrier,
no conjugation
Low cytotoxicity on NR8383 cells; sustained release in
0.8% normal saline media
[139]
N-acetyl galactosamine, 4-SO4GalNAc) of the mannose receptor
was used with the aim to target infectedmacrophages in leishma-
niasis. Coating of amphotericin B-loaded liposomes with this lig-
and led to an enhanced cellular uptake on macrophage cell lines
compared to palmitoyl mannose modified liposomes.[127]
3.3.2. Folate Receptor Targeting
Folic acid is an essential vitamin. Its derivatives are required for
single carbon transfer reactions, among others, for the biosyn-
thesis of nucleotide precursors in mammalian cells. Folate re-
ceptors mediate the uptake of folic acid derivatives into cells
by endocytosis. Among the different isoforms of folate recep-
tors, folate receptor 𝛽 is overexpressed on the surface of acti-
vated macrophages that are involved in inflammatory and au-
toimmune diseases, and also on tumor-associated macrophages
(TAMs).[128–130] In addition, folate receptor 𝛼 is upregulated in
many types of cancer cells.[130–132] Therefore, folic acid and fo-
late derivatives have been widely used as promising ligands
to selectively deliver imaging and therapeutic agents to can-
cer cells, TAMs, and activated macrophages in inflammatory
diseases.[130–133] However, less studies have focused on the poten-
tial of macrophage targeting with folate functionalized nanocar-
riers in the field of intracellular infections. Such examples are
the folic acid-decorated antiretroviral drug nanoformulations that
displayed enhanced uptake by monocyte-derived macrophages
and enhanced antiretroviral activities compared with nontar-
geted particles. With the targeted formulations, favorable phar-
macokinetic and biodistribution profiles were achieved follow-
ing intramuscular administration.[134,135] As other example, in a
murine model of pulmonary Pseudomonas aeruginosa infection,
folic acid-decorated,MXF-loaded 𝛼-cyclodextrin-based nanoparti-
cles showed better antibacterial efficacy with a prolonged survival
time than the free drug and nontargeted nanoparticles.[136]
Regarding TB, targeting the folate receptor has not been a well-
exploited approach so far. The findings of two studies are summa-
rized in Table 4. Recently, Shah et al. demonstrated promising re-
sults in the targeted delivery of anti-TB-drug-loaded nanocarriers.
RIF-loaded oleic acid-based nanoemulsion with chitosan–folate
coating was prepared for pulmonary delivery. This nanoemulsion
was nebulized and the obtained aerosol provided optimal char-
acteristics for deep lung deposition. The nanoemulsions had no
cytotoxicity in vitro on AMs and the chitosan–folate-coated na-
noemulsions had better cellular uptake than the chitosan-coated
nanoemulsions without folate modification. It is presumed that
cell internalization was facilitated by both folate and mannose
receptors (since chitosan has N-acetylglucosamine residues that
can be recognized by mannose receptors). Moreover, the folate-
grafted formulation led to a higher lung drug content in vivo and
reduced plasma drug concentration as compared to nonfunction-
alized formulations.[137] Similar approach was applied success-
fully using folate-grafted chitosan coating for SLNs to reach lung
tissues by inhalation, although the objective of the work was fo-
cused on lung cancer therapy and not TB.[138]
In another study with the aim of developing better thera-
peutic approach against TB, folate had dual role: targeting lig-
and and building block of a self-assembled structure, namely
liquid-crystalline folate nanoparticles. RIF intercalated between
or within the ordered folate stacks of the nanoparticles, and
an efficient RIF loading was achieved with sustained release.
Cellular uptake of this construct, however, was not adequately
characterized.[139]
3.3.3. Hyaluronic Acid Receptor Targeting
Hyaluronic acid (hyaluronan, HA) is a glycosaminoglycan con-
sisting of repeating disaccharide units of d-glucuronic acid and
N-acetyl-d-glucosamine.[140] HA is a major component of the
pericellular and extracellular matrix (ECM), it is present in the
tissues all over the body and indicates healthy or inflamed
conditions upon its interaction with immune cells. The high-
molecular-weight HA (>1000 kDa) predominates in healthy
tissues and it has immunosuppressive and anti-inflammatory
properties, while low-molecular-weight HA (<500 kDa) forms
upon tissue damage or infection as the components of ECM
become fragmented and it exhibits immunostimulatory and
proinflammatory properties. During inflammatory response, ac-
tivated immune cells upregulate CD44, the HA binding recep-
tor. CD44 is highly expressed on macrophages, moreover, AMs
can bind HA also during homeostatic (noninflammatory) condi-
tions. Macrophages take up HA in a CD44-dependent manner,
then it is transported to the lysosomes.[141,142] In addition, CD44
is also a macrophage-binding site for Mtb[143] and the bacteria
can utilize HA as a carbon source for multiplication.[144] Besides
CD44, several HA-binding and HA-interacting receptors were
also found, including TLR2 and TLR4 that are highly expressed
on macrophages. HA fragments induce inflammatory gene ex-
pression (chemokine and cytokine expression) in macrophages
through TLR2 and TLR4.[140,141] HA is biocompatible, biodegrad-
able and has several modification sites that makes it an attractive
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Table 5. Examples of active targeting via hyaluronic acid receptor in nanotechnology-based anti-TB drug delivery systems.
a)








Moderate cytotoxicity; enhanced uptake on MH-S
cells; phagocytosis, CD44-mediated endocytosis;





RIF, INH, verapamil HA-based nanocarrier,
no conjugation
Spray-dried nanocomposite; low MIC values on
extracellular bacteria (H73Rv, MDR, and XDR
strains); low cytotoxicity on PBMC-derived
macrophages; good anti-TB activity on intracellular












Reduced cytotoxicity of AMP in nanogel form on
BMDM (cytotoxic concentration is more than
23-fold higher than in case of free AMP); successful
internalization by BMDM; intracellular inhibition of
bacteria in BMDM infected withM. avium 2447 or
Mtb H37Rv; reduced bacterial level in the lungs in
C57BL/6 mice (infection by inhalation exposure)









Spray-dried microspheres; enhanced uptake on RAW
264.7 cells (air–liquid culture method); lower
plasma concentration, higher lung accumulation in
case of intratracheally administered microspheres
as compared to i.v. and oral administration (OFX








Spray-dried microspheres; loss of cell viability of A549




candidate to be used directly as a carrier or as targeting ligand
on the surface of nanocarriers. Moreover, the immunomodula-
tory role of HA also could be exploited to boost strategies against
infectious diseases, such as TB.[145] HA is widely studied as part
of drug delivery systems not only against infections but also in
cancer therapy because CD44 is also overexpressed on different
cancer cells.[146] Recent findings on active targeting of anti-TB-
drug-loaded nanocarriers via HA receptor are summarized in Ta-
ble 5.
Hyaluronic acid–tocopherol succinate micelles enhanced the
in vitro uptake of the incorporated RIF in AMs via phagocytosis
and CD44-receptor-mediated endocytosis. These micelles could
activate macrophages and trigger the secretion of proinflamma-
tory cytokines and chemokines, thus enhancing the uptake of
RIF-loaded micelles. These effects could lead to a more efficient
RIF therapy against TB.[147]
Respirable particles were prepared from nanosuspension of
sodium hyaluronate, RIF, INH, and verapamil, an efflux pump
inhibitor. The highly respirable microparticles showed success-
ful intracellular anti-TB activity on both susceptible and resistant
Mtb strain-infected macrophages.[148]
Silva et al. encapsulated the LLKKK18 antimicrobial peptide
(AMP) into self-assembling HA nanogels. With this formulation,
the cytotoxicity of LLKKK18 was outstandingly reduced in vitro
on murine-bone-marrow-derived macrophages as compared to
the free AMP. The HA nanogels also enhanced the stability
of the peptide by means of reduced proteolytic degradation in
the macrophages. Incubation of macrophages with AMP-loaded
nanogel reduced the intracellular levels of both the opportunistic
M. avium and Mtb in vitro. Importantly, intratracheal adminis-
tration of AMP-loaded HA nanogels with low peptide concentra-
tion significantly reduced bacterial levels in the lungs of the mice
infected with M. avium or Mtb. Unloaded HA nanogels also re-
duced the infection levels in infected mice to a lesser extent.[149]
In a study of Hwang et al., hyaluronan microspheres con-
taining ofloxacin (OFX) were prepared using a spray-drying
method. The uptake of the microspheres was examined on an
AM cell line using air–liquid culture method as a suitable in
vitro model for airway drug uptake studies. OFX uptake from
the HA microspheres was greater compared to plain OFX mi-
crospheres and nonformulated OFX. Importantly, the micro-
spheres administered intratracheally resulted in a reduced sys-
temic bioavailability and the highest lung accumulation com-
pared to the oral and intravenous injection of nonformulated
OFX solution. They presumed that the HA microspheres form
a gel-like layer on the lung surface upon contact with the mu-
cus fluid due to the mucoadhesiveness of HA that consequently
provokes an enhanced uptake.[150] The aerosol performance (res-
pirability) of HAmicroparticles obtained by spray drying was im-
proved when surfactants were included in the formulations as
an encouraging step to get closer to the clinical use of such HA
formulations.[151]
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Table 6. Examples of active targeting via tuftsin receptor in nanotechnology-based anti-TB drug delivery systems.
a)
Nanocarrier Loading Ligand, method Key findings Ref.
PLGA NPs with Pluronic
F127






Drug–peptide conjugate: no cytotoxicity on PBMC, no
hemolytic activity on human erythrocytes, enhanced activity
on extracellular and intracellular bacteria (MonoMac6 cells
infected withMtb H37Rv); nanoparticle: after oral
administration no toxicity in lung, spleen, liver, kidney,
significantly decreased bacterial load, decreased
inflammation and minimal granulomatous involvement
compared to untreated control in guinea pigs (infected by
intramuscularMtb H37Rv injection)
[161,162]







and aldehyde group of
modified Pluronic F127
Enhanced cellular uptake on MonoMac6; enhanced
intracellular anti-TB activity onMtb-infected MonoMac6
[163]




RIF, FITC Oleic acid was attached to
the N-terminus of tuftsin
Low cytotoxicity; improved uptake on J774A.1 cells; improved





RIF Palmitoyl tuftsin, C-terminus




RIF delivered twice weekly for 2 weeks in i.v. administered
liposomes was at least 2000 times more effective than the
free drug in lowering the load of lung bacilli inMtb
H37Rv-infected Swiss albino mice (i.v. infection); lowered
bacterial load in liver, spleen; increased mean survival time
[165]
a)Abbreviations: MonoMac6: human monocytic cell line; Pluronic F127: poly(ethylene oxide)/poly(propylene oxide)/poly(ethylene oxide), PEO–PPO–PEO triblock copolymer.
3.3.4. Tuftsin Receptor Targeting
Tuftsin is a natural tetrapeptide (Thr-Lys-Pro-Arg), produced by
enzymatic cleavage of the Fc domain of the heavy chain of
immunoglobulin G by two enzymes, a neutrophil-derived en-
zyme leukokininase and spleen tuftsin endocarboxypeptidase.
Tuftsin and its analogs have a wide spectrum of biological ac-
tivity, their wide range of immunostimulatory activity results
in increased antimicrobial and antitumor properties. They can
activate various components of the immune system, including
macrophages, importantly they stimulate phagocytosis, pinocy-
tosis, and chemotaxis.[152,153] Tuftsin also has effects on the ner-
vous system.[154] Although tuftsin receptor was identified from
themembrane of rabbit peritoneal granulocytes,[152,155] themech-
anism of action and signaling pathway of tuftsin is still not fully
understood. Monocytes and macrophages also possess specific
receptors for tuftsin.[154] It was described that tuftsin also binds to
neuropilin-1 that can be found inmost tissues, and it plays a role,
among others, in angiogenesis and axonal guidance.[156,157] Re-
cent findings on active targeting of anti-TB-drug-loaded nanocar-
riers via tuftsin receptor are summarized in Table 6.
Several tuftsin-based carriers were developed[158] and were
used for TB targeting as drug–peptide conjugates, these conju-
gates efficiently inhibited the intracellular bacteria in infected
macrophage models.[159,160] Due to its quick biodegradation, the
use of this peptide as targeting ligand is more suitable in a
nanocarrier-based formulation.
In the studies of Horváti et al., INH or a drug candidate pyri-
dopyrimidine derivative was covalently conjugated to a palmitoy-
lated tuftsin derivative. The drug–lipopeptide conjugates were
successfully encapsulated into PLGA nanoparticles stabilized
with Pluronic F127 block copolymer.[161,162] For in vivo studies,
infected guinea pigs were used since they are highly suscepti-
ble to infection with Mtb and develop the disease similarly as in
humans.[56] The orally administered conjugate-loaded nanopar-
ticles were able to decrease the bacterial level and no toxicity was
observed, while in untreated control animals, progression of the
disease was observed (severe lesions, parenchymal involvement,
necrosis, intralesional mineralization).[161,162] This approach was
further developed by grafting tuftsin derivative on the surface
of a drug-candidate-loaded PLGA nanoparticle in the form of
peptide–Pluronic F127 conjugate, thus enhanced cellular up-
take and intracellular anti-TB activity was achieved compared to
the free drug candidate and the nongrafted nanoparticles.[163]
Similar in vitro results were achieved with NLCs where oleic
acid-elongated tuftsin derivative was incorporated into the
carrier.[164]
Drug-loaded liposomes with palmitoyl tuftsin anchored in the
liposome bilayer by the long hydrophobic fatty acid part were ef-
fective in vivo not only against TB but also against infections,
such as malaria, leishmaniasis, and fungal infections.[165,166] RIF
delivered in these tuftsin-bearing liposomes was outstandingly
more effective than the free drug or nongrafted liposomes in low-
ering the bacillary load in lungs of infected animals.[165]
3.3.5. Targeting of Formyl Peptide Receptors (FPRs)
FPRs (three subtypes: FPR1, FPR2, and FPR3) are key play-
ers in innate immunity, they mediate host-defense and in-
flammatory responses. These chemoattractant receptors are
mainly expressed on innate immune cells including neutrophils,
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monocytes, and macrophages, however, other cell types also ex-
press some FPRs. The first ligands defined for FPRs were N-
formyl peptides, such as N-formylated methionine containing
peptides (e.g., N-formylmethionyl-leucyl-phenylalanine (fMLF))
that are cleavage products of bacterial and mitochondrial pro-
teins, therefore, FPRs are considered as PRRs. Subsequently, sev-
eral structurally diverse ligands have been identified for these
receptors.[167–169] This wide range of ligands for FPRs offers the
opportunity to create a plethora of FPR targeting nanocarriers.
With fMLF-grafted liposomes, enhanced in vitro macrophage
uptake and in vivo inflammatory site targeting was observed.[170]
PEG-based nanocarriers modified with fMLF were developed for
targetingmacrophages in anti-HIV therapy.[171] In case of TB, the
immune response boosting effect of FPR agonists was demon-
strated. Treatment via subcutaneous route of Mtb-infected mice
(infected intranasally or injection via lateral tail vein) with N-
formylated peptides with or without anti-TB drugs showed im-
munotherapeutic potential since the bacterial load was markedly
reduced in lungs and spleen as compared to the untreated
mice.[172,173] Moreover, FPR1 ligand peptide–PEG conjugate was
used in in vitro and in vivo granulomamodels as a potential imag-
ing biomarker for the tuberculosis granuloma.[174] These find-
ings show the potential of macrophage targeting through FPRs
in TB, however, this area is far from being exploited yet.
3.3.6. Other Receptors
Besides the presented macrophage receptors, other receptors
can be also targeted. Macrophages have phenotypic heterogene-
ity and functional plasticity depending on their developmen-
tal origins, local environment, and disease progression.[175,176]
Therefore, depending on the characteristic macrophage pop-
ulations that are aimed to be targeted, a wide range of re-
ceptors can be considered, beside the ones that are presented
above. Especially, in case of pulmonary macrophages, receptors
– such as CD14 (lipopolysaccharide (LPS) receptor), CD200R,
CD115 (colony stimulating factor 1 receptor), CD71 (transfer-
rin receptor), Dectin-1/2 (𝛽-glucan receptor), scavenger recep-
tors (SR-A, CD36 (SR-B), macrophage receptor with collage-
nous structure (MARCO), CD163, CD204, CD68), TLRs (TLR4,
TLR9), and Fc receptors (CD64, CD32, CD16) – can open up
new strategies.[177] Targeting other host cells of Mtb also could
be promising in overcoming the disease. For example, in den-
dritic cells, the main receptor involved in Mtb recognition is
dendritic cell-specific intercellular adhesion molecule-3 grab-
bing non-integrin (DC-SIGN), a C-type lectin receptor, that can
be also targeted.[178,179] In addition, alongside the targeting lig-
ands presented here, a large spectrum of other ligands were ap-
plied to target nanocarriers toward macrophages. These studies,
beside tuberculosis, mainly focused on targeting macrophages
in cancer and different inflammatory diseases.[101,129,180–184] In
TB treatment, mycolic acids,[185] lactose,[186] fucoidan,[187] im-
munoglobulin G,[188] maleylated bovine serum albumin,[189] O-
steroyl amylopectin,[189] surface ligands, or nanoparticle com-
ponents proved to be promising candidates. Altogether, the so
far obtained knowledge about macrophage (and other host cell)
receptors and ligands provides a platform to develop novel ap-
proaches for an effective drug-delivery system.
4. Challenges and Future Perspectives
In recent decades, we have witnessed an extraordinary increase
in our basic knowledge on TB. The sequencing of the first Mtb
genome, in 1998,[190] opened the way to molecular studies from
the pathogen perspective, which would result eventually in the
discovery of novel drug targets and the identification of virulence
factors. Diverse omics technologies have expanded vastly our cur-
rent understanding of all stages of the disease, also from the host
side.
In fact, tuberculosis, i.e., the “white plague” has been a real
pandemic for centuries. Oldest remains of people suffering from
TB have been dated 9000 years ago. Between XVII and XIX cen-
turies, 25% of deaths in Europe were caused by TB.[191] Only dur-
ing the XX century, the incidence of tuberculosis started to de-
cline, thanks to the discovery of a vaccine and the development
of a drug-based treatment, although from the 1990s, despite ma-
jor medical advances, the tuberculosis pandemic raised again (an
important lesson to be learnt when considering the pandemic we
are living in our days), especially in the low-income countries.
Poverty is hence the first challenge for tuberculosis control that
will need to be addressed: up to 87% of tuberculosis global cases
are located in just 25 developing countries plus the five BRICS
emerging economies (Brazil, Russian Federation, India, China,
and South Africa), whereas the same list of countries accounts
for 34% of global COVID-19 cases. In a drastic contrast, the Eu-
ropean region (excluding Russia) plus the USA account for 1.9%
of tuberculosis and 41% of COVID-19 global cases, respectively
(as of 9 July 2020).[1,192]
Nanotechnology offers a powerful tool in the fight against TB.
Moreover, combining nanocarrier-based drug delivery systems
with pulmonary administration route provides the most encour-
aging approach in TB treatment. Applying pulmonary drug de-
livery devices constitutes a noninvasive mode for drug adminis-
tration with a bright future even for the administration of drugs
for systemic action.[193] Importantly, the development of a sus-
tainable nanomedicine-based approach that can be used with
pulmonary administration is a key pillar in the control of this
disease in developing countries, where the majority of the pop-
ulation do not access appropriate health care.[194] The nanofor-
mulations with inhaler devices can be self-administered, thus it
can give an opportunity to an easier and more accessible anti-TB
drug treatment, reducing the need for complex medical equip-
ment, medical personnel, and the overall costs of the treatment.
Despite the increasing number of publications demonstrating
the advantages of respiratory administration, the lack of effec-
tive and uniform administration techniques in preclinical mod-
els generally results in poor translational success. Basically, the
use of devices for respiratory administration involves the passive
inhalation of the drug formulation, resulting in variations in the
delivered dose. An accurate estimation of the dose delivered to
the lungs is crucial since the poor delivery efficiency due to the
drug loss in the reservoir, tubing of the aerosol generator, delivery
accessories, and the nasopharyngeal region of the animal, can be
misunderstood with a low efficacy of the treatment, and it may
constitute a risk factor for development of drug resistance. For
these reasons, invasive techniques, such as intratracheal instil-
lation, are preferred to achieve higher and precise dosing of the
drugs in the lungs, thus most preclinical models are markedly
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different from inhalationmethodologies used in humans.[80] It is
crucial to consider the anatomical differences between humans
and model animals of pulmonary diseases. Humans can inhale
a substantial dose of aerosol from an inhaler device in a single
deep breath. To correctly assess efficacy of the inhalation admin-
istration, the fabrication of high-quality devices, capable of de-
positing an efficacious drug dose into a the lungs of a sponta-
neously breathing animal is fundamental.[195] Furthermore,most
of the inhaler using patientsmakes technical errors in inhalation,
therefore, it is crucial to provide appropriate training and instruc-
tions for inhaler application.[196,197]
In recent years, there has been a continuously increasing in-
novation and patents filing in the development and perfection
of devices for pulmonary drug delivery. Parallelly, improving and
adapting the drug formulations to these devices and administra-
tion route is needed. In the following years, nano-enabled en-
gineering of the particles and formulations will contribute to
increasing the amount of drug that reaches the lungs and the
stability of the formulation. In this line, patents are being filed not
only on pulmonary drug delivery systems but also on their com-
bination with old pulmonary-targeted drugs whose formulations
have been adapted.[193] Undoubtedly, these innovation efforts will
increase in the following years and broaden to include the simul-
taneous administration of anti-TB drugs via this administration
route for simplification of treatment and seeking synergic effects.
Drug encapsulation pursues the improvement of antimicro-
bial drugs in several ways, i.e., increasing solubility, avoiding a
rapid clearance, or minimizing negative side effects. However,
if the nanoparticle does not contain any effect per se, it will
somehow dilute the drug since it will work as an excipient. Con-
sequently, the nanoparticle system should display high loading
capacity in order to minimize the amount of material admin-
istered. We can foresee that increasing the loading of nanopar-
ticles will result in a new generation of drug-loaded nanopar-
ticles, aiming at lowering the dose but with better therapeutic
effect. Further, techniques as microfluidics[198] and sequential
nanoprecipitation[199] provide a straightforward approach to get
access to high loading capacity systems. Encapsulation of hy-
drophilic drugs, as some second line anti-TB drugs, is challeng-
ing with many nanocarrier systems. Increasing effort to improve
their encapsulation can be done by chemical conjugation via hy-
drolysable or responsive chemical bonds,[200] or by using systems
suitable for hydrophilic drugs, such as liposomes, niosomes, or
polymeric nanocapsules. Several second line anti-TB drugs have
limited or no ability to penetrate cells, which impacts their effi-
cacy and makes higher doses necessary. Their encapsulation in
nanocarriers should aim at allowing the selective distribution to
phagocytic cells and enhancing the uptake of the encapsulated
drug by the cells. Resulting improved bioavailability will allow de-
creasing the dose and the severity of accompanying side effects.
Moreover, improvements are particularly needed in the strategies
for second line anti-TB drug encapsulation due to the rapid emer-
gence of MDR-TB.[201]
Drug delivery applications typically require the surface modi-
fication or functionalization of the nanoparticles to improve sta-
bility, biocompatibility, incorporate targeting moieties, and thus
achieve better selectivity. A wide range of strategies have been
used to modify the surface of nanoparticles or functionalize
nanoparticles with a variety of ligands.[202] These strategies can
bear hurdles and creating more specific and complex nanoparti-
cles with more than one functionalizing ligand is a very challeng-
ing task and it is rarely used. The chemicals that are included in
the surface grafting procedures can have a significant effect on
nanoparticle properties. Furthermore, precise characterization is
required on the qualitative and quantitative presence of the lig-
ands and modifying agents attached to the surface. It is impor-
tant to control the surface orientation of the targeting ligands
and confirm that they retain their native binding affinity for the
receptor of interest. The adequate purification of these nanopar-
ticles often encounters difficulties, resulting in the presence of
residual reagents that may not have been removed during pu-
rification. Further advances in attachment strategies, conjugation
efficiency, characterization, purification, and scale-up feasibility
are needed to develop optimized, robust, and simple methods for
such nanoparticle engineering.[202,203]
In summary, it is necessary to stress the importance of the
reproducibility in the production (drug loading, encapsulation,
and functionalization efficiency, physicochemical properties) of
drug-loaded nanocarriers and the possibility of scaling the pro-
cess. The lack of proper and specific regulatory guidelines re-
garding characterization, study designs, and statistical analyses
represents a general obstacle in the clinical translation of
nanoformulations. Optimized sharing practices are also needed
to promote the translation of nanotechnology from experimental
success to clinical practice.[204–209]
5. Conclusion
During the last 25 years, nanotechnology has emerged as a new
strategy to improve drug delivery and efficiency of the actual treat-
ments. However, many of the most successful nanoformulations
are focused on cancer treatment and only few of them are ori-
ented for infectious diseases. It is crucial to integrate key en-
abling technologies, including nanotechnology, to make a quan-
tum leap for controlling pandemics. In this progress report, we
highlighted the main challenges and potential of nanopharma-
ceutics for tuberculosis treatment. The improvement on the sta-
bility and solubility of active principles, and the possibility to di-
rect the drug to a specific target make nanocarriers as a new
opportunity to develop more effective treatments. Importantly,
the improved bioavailability and biodistribution allows decreas-
ing the dose and the severity of accompanying side effects. These
advances also contribute to reducing the emergence of drug-
resistant strains. Although it seems promising, so far nanotech-
nology has not provided any product in the market for this dis-
ease, and the number of patents in the field ismuch lower than in
the case of nanomedicines for cancer. To achieve groundbreaking
progress and to make the pulmonary administration of nanopar-
ticles feasible for noninvasive clinical trials, a multidisciplinary
approach is necessary: nanotechnology, medicine, and engineer-
ing must collaborate.
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G. Mező, V. Grolmusz, B. Vértessy, F. Hudecz, S. Bősze, Tuberculosis
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